Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 5, 2015, Pages 915-923

  Yang, Yu ^a   Xu, Haineng ^a   Huang, Weidan ^a   Ding, Miao ^a   Xiao, Jing ^b   Yang, Dongmei ^c   Li, Huaguang ^a   Liu, Xin Yuan ^a,c   Chu, Liang ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b HENAN NORMAL UNIVERSITY   (China)

^c ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

A549 sphere cells; Apoptosis; Lung cancer stem like cells; Oncolytic adenovirus; ZD55 TRAIL

Indexed keywords

ADENOVIRIDAE; MUS;

2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; BENZOQUINONE DERIVATIVE; CHROMONE DERIVATIVE; EMBELIN; ENZYME INHIBITOR; GREEN FLUORESCENT PROTEIN; MORPHOLINE DERIVATIVE; ONCOLYTIC VIRUS; RESVERATROL; STILBENE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRIDAE; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CANCER STEM CELL; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLUORESCENCE MICROSCOPY; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; ONCOLYTIC VIROTHERAPY; PROCEDURES; TUMOR CELL LINE; TUMOR VOLUME; VIROLOGY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; ENZYME INHIBITORS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUNG NEOPLASMS; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MORPHOLINES; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; STILBENES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928435553     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12397     Document Type: Article

References (48)

1. Zeng HM, Zheng RS, Zhang SW, et al. Lung cancer incidence and mortality in China, 2008. Thorac Cancer. 2013; 4: 53-8.
2. Chen WQ, Zheng RS, Zhang SW, et al. Lung cancer incidence and mortality in China, 2009. Thorac Cancer. 2013; 4: 102-8.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
4. Alamgeer M, Peacock CD, Matsui W, et al. Cancer stem cells in lung cancer: evidence and controversies. Respirology. 2013; 18: 757-64.
5. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009; 115: 5218-27.
6. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993; 11: 336-44.
7. Wisnivesky JP, Yankelevitz D, Henschke CI. Stage of lung cancer in relation to its size: part 2. Evidence. Chest. 2005; 127: 1136-9.
8. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645-8.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100: 3983-8.
10. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63: 5821-8.
11. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445: 111-5.
12. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008; 15: 504-14.
13. Carney DN, Gazdar AF, Bunn PA Jr, et al. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells. 1982; 1: 149-64.
14. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA. 2009; 106: 16281-6.
15. Leung EL, Fiscus RR, Tung JW, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS ONE. 2010; 5: e14062.
16. Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007; 67: 4827-33.
17. Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009; 7: 330-8.
18. Qiu X, Wang Z, Li Y, et al. Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Cancer Lett. 2012; 323: 161-70.
19. Heinen CD, Goss KH, Cornelius JR, et al. The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway. Gastroenterology. 2002; 123: 751-63.
20. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 2009; 14: 3-9.
21. Gangemi R, Paleari L, Orengo AM, et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem. 2009; 16: 1688-703.
22. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007; 58: 267-84.
23. Kanai R, Rabkin SD, Yip S, et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012; 104: 42-55.
24. Wang H, Chen NG, Minev BR, et al. Oncolytic vaccinia virus GLV-1 h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. J Transl Med. 2012; 10: 167.
25. Marcato P, Dean CA, Giacomantonio CA, et al. Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther. 2009; 17: 972-9.
26. Cripe TP, Wang PY, Marcato P, et al. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther. 2009; 17: 1677-82.
27. Ribacka C, Hemminki A. Virotherapy as an approach against cancer stem cells. Curr Gene Ther. 2008; 8: 88-96.
28. Zhang X, Komaki R, Wang L, et al. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res. 2008; 14: 2813-23.
29. Eriksson M, Guse K, Bauerschmitz G, et al. Oncolytic adenoviruses kill breast cancer initiating CD44 + CD24-/low cells. Mol Ther. 2007; 15: 2088-93.
30. Pei Z, Chu L, Zou W, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology. 2004; 39: 1371-81.
31. Ding M, Cao X, Xu H, N, et al. Prostate Cancer-Specific and Potent Antitumor Effect of a DD3-Controlled Oncolytic Virus Harboring the PTEN Gene. Plos One. 2012; 7.
32. Xu HN, Huang WD, Cai Y, et al. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy. Mol Cancer. 2011; 10: 133.
33. Zhao L, Gu J, Dong A, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther. 2005; 16: 845-58.
34. Vellanki SH, Grabrucker A, Liebau S, et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia. 2009; 11: 743-52.
35. Liang D, Shi Y. Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma. Med Oncol. 2012; 29: 633-9.
36. Wang P, Suo Z, Wang M, et al. In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines. Exp Hematol Oncol. 2013; 2: 16.
37. Broadley KW, Hunn MK, Farrand KJ, et al. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells. 2011; 29: 452-61.
38. Siegelin MD, Gaiser T, Siegelin Y. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int. 2009; 55: 423-30.
39. Tong Y, Zhu WW, Huang XB, et al. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncol Rep. 2014; 31: 1581-8.
40. Sachlos E, Risueno RM, Laronde S, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012; 149: 1284-97.
41. Wurdak H, Zhu S, Romero A, et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell. 2010; 6: 37-47.
42. Goidts V, Bageritz J, Puccio L, et al. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene. 2012; 31: 3235-43.
43. Jang JY, Kim MK, Jeon YK, et al. Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells. Exp Mol Med. 2012; 44: 251-9.
44. Shih IeM, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 2007; 67: 1879-82.
45. Tang SN, Fu J, Nall D, et al. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer. 2012; 131: 30-40.
46. Lu D, Choi MY, Yu J, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA. 2011; 108: 13253-7.
47. Bauerschmitz GJ, Ranki T, Kangasniemi L, et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res. 2008; 68: 5533-9.
48. Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007; 99: 1410-4.